Rheumatoid arthritis
Conditions
Interventions
None listed
Sponsors
Tokyo Medical and Dental University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients must meet the following criteria to be eligible for study entry 1. Fulfill the 2010 ACR/EULAR classification criteria for RA. 2. Patients (age >= 20) should have ability and willingness to provide written informed consent and to comply with the requirement of the protocol. 3. Have started treatment with molecular targeting drugs or MTX. A patient who started treatment with these drugs within 30 days is also allowed.
Exclusion criteria
Exclusion criteria: A patient who has any of the following will be excluded from our study. 1. When a patient withdraw consent to this study 2. When a patient is participating in a clinical trial for approval of drugs at the enrollment. 3. When a patient is regarded as inappropriate to join the study based on medical reasons or other rational reasons by attending physicians' discretion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Safety outcomes : Incidence rate and type of serious adverse events 2.Efficacy outcomes : Clinical response over time by EULAR response criteria | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Safety outcomes : Mortality, Risk factor for serious adverse event 2.Efficacy outcomes : Achievement rates of remission or low disease activity status, achievement of functional remission, drug retention rates. | — |
Countries
Japan
Contacts
Public ContactMarie Yajima
Tokyo Medical and Dental University Department of Pharmacovigilance
Outcome results
None listed